Open-source FlexNIRS: A low-cost, wireless and wearable cerebral health tracker.
Bluetooth low energy
Cerebral oximetry
Community health
NIRS
Wearable device
Journal
NeuroImage
ISSN: 1095-9572
Titre abrégé: Neuroimage
Pays: United States
ID NLM: 9215515
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
received:
09
11
2021
revised:
30
03
2022
accepted:
13
04
2022
pubmed:
23
4
2022
medline:
27
5
2022
entrez:
22
4
2022
Statut:
ppublish
Résumé
Currently, there is great interest in making neuroimaging widely accessible and thus expanding the sampling population for better understanding and preventing diseases. The use of wearable health devices has skyrocketed in recent years, allowing continuous assessment of physiological parameters in patients and research cohorts. While most health wearables monitor the heart, lungs and skeletal muscles, devices targeting the brain are currently lacking. To promote brain health in the general population, we developed a novel, low-cost wireless cerebral oximeter called FlexNIRS. The device has 4 LEDs and 3 photodiode detectors arranged in a symmetric geometry, which allows for a self-calibrated multi-distance method to recover cerebral hemoglobin oxygenation (SO
Identifiants
pubmed: 35452803
pii: S1053-8119(22)00340-8
doi: 10.1016/j.neuroimage.2022.119216
pii:
doi:
Substances chimiques
Hemoglobins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
119216Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM116177
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD091067
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG072481
Pays : United States
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest DHS has a financial interest in Niji Corp, a company developing a suite of home/remote usage digital biomarker tools for the identification and assessment of individuals with Alzheimer's disease. MAF has a financial interest in 149 Medical, Inc., a company developing diffuse correlation spectroscopy technology for assessing and monitoring cerebral blood flow in newborn infants. DHS and MAF interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies.